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ABSTRACT
Colorectal cancer (CRC) is rapidly increasing in Asia,
but screening guidelines are lacking. Through
reviewing the literature and regional data, and using the
modified Delphi process, the Asia Pacific Working Group
on Colorectal Cancer and international experts launch
consensus recommendations aiming to improve the
awareness of healthcare providers of the changing
epidemiology and screening tests available. The inci-
dence, anatomical distribution and mortality of CRC
among Asian populations are not different compared with
Western countries. There is a trend of proximal migration
of colonic polyps. Flat or depressed lesions are not
uncommon. Screening for CRC should be started at the
age of 50 years. Male gender, smoking, obesity
and family history are risk factors for colorectal neoplasia.
Faecal occult blood test (FOBT, guaiac-based and
immunochemical tests), flexible sigmoidoscopy and
colonoscopy are recommended for CRC screening.
Double-contrast barium enema and CT colonography
are not preferred. In resource-limited countries, FOBT is
the first choice for CRC screening. Polyps 5–9 mm in
diameter should be removed endoscopically
and, following a negative colonoscopy, a repeat
examination should be performed in 10 years.
Screening for CRC should be a national health priority in
most Asian countries. Studies on barriers to CRC
screening, education for the public and engagement of
primary care physicians should be undertaken. There is no
consensus on whether nurses should be trained to
perform endoscopic procedures for screening of colorectal
neoplasia.
Colorectal cancer (CRC) is one of the most
common cancers in Asia and its incidence is
rising in a number of Asian countries, yet there
are no national or regional guidelines on preven-
tion and screening for early diagnosis of this
important disease. The Asia Pacific Working
Group on Colorectal Cancer was established in
2004. The group has since conducted several
studies and accumulated/published local data on
neoplasm of the colon. In 2007, the Working
Group members felt that it was time to review
regional data on CRC and colorectal neoplasia in
Asia in order to draft guidelines and recommenda-
tions in the screening and prevention of CRC in
Asia.
The aim of this Consensus Conference was to
draw up recommendations for CRC screening
suitable for Asia.
METHOD
Membership of the consensus group
Members of the Consensus Group were selected
using the following criteria: (1) demonstrated
knowledge/expertise in CRC by publication/
research or participation in national or regional
guidelines; (2) geographical representation of the
Asia Pacific countries/region; (3) diversity of views
and expertise in the healthcare system (including
primary care doctor, surgeon, pathologist, health
economist, epidemiologist, public health expert,
nurse specialists); and (4) stakeholders representing
different interest groups (including healthcare
policy makers, representatives from patient groups
and non-government organisations). Besides mem-
bers from the Asia Pacific Working Group on
Colorectal Cancer, the American Cancer Society
(represented by D Brooks) and the Prevent Cancer
Foundation of the United States (represented by C
Aldige) as well as the International Digestive
Cancer Alliance and OMED (represented by G
Young) were invited to participate in this con-
ference as overseas experts. D A Lieberman was
invited on his personal capacity as an advisor in
this conference. The voting members are listed in
Appendix A.
Literature search
Comprehensive literature reviews were carried out
by the Steering Committee on a number of topics,
namely (1) epidemiology of CRC in Asia; (2)
colorectal polyps; (3) methods for CRC screening;
(4) risk stratification; and (5) policy in CRC
screening. We identified relevant articles published
in English using MEDLINE, EMBASE and the
Cochrane Trials Register in human subjects from
1990 to 2007. National and international guidelines
on CRC screening were solicited. Searches on
meeting abstracts (Asia Pacific Digestive Week
(APDW), American College of Gastroenterology
(ACG), American Gastroenterological Association
(AGA), American Society of Gastrointestinal
Endoscopy (ASGE), British Society of
Gastroenterology (BSG), United European
Gastroenterology Week (UEGW)) and review
articles were limited to the preceding 5 years. The
panel members received a copy of the relevant
articles before the first iteration. The reviews were
presented at the Consensus Conference before the
second iteration.
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Modified Delphi process
The modified Delphi process was adopted to develop the
consensus.1 The Delphi process is a method for developing
consensus using a combination of the principles of evidence-
based medicine and anonymous voting. After a systematic
literature review, change of views from the Consensus Panel
was encouraged. The process was completed by grading of
evidence and anonymous voting on a series of iterations of the
statements. The Steering Committee (JJYS, JYWL and FKLC)
drafted a list of statements and circulated it electronically in
advance to panel members. After reading the reviews, each
member rated the statements on a Likert scale anchored by 1–5
(1, accept completely; 2, accept with some reservation; 3, accept
with major reservation; 4, reject with reservation; 5, reject
completely). All votes are anonymous. The first vote was
conducted for the entire Consensus Group electronically by e-
mail, without explanation or justification of the statement.
Feedback of the statements was collated. The results and
comments were returned to the Steering Committee before the
meeting. Consensus was considered to be achieved when >80%
of the voting members indicated ‘‘Accept completely’’ or
‘‘Accept with some reservation’’. A statement was refuted
when >80% of the voting members indicated ‘‘Reject com-
pletely’’ or ‘‘Reject with reservation’’.
A face-to-face meeting of the entire group was held on 15–16
September 2007 to review the evidence of statements that
reached consensus and discuss those statements that did not
reach consensus on the first iteration. A series of didactic
lectures presented by members reviewed the literature on five
topics in colorectal neoplasia, namely (1) Epidemiology of CRC
in Asia; (2) Colorectal polyps; (3) Methods for CRC screening;
(4) Risk stratification; and (5) Policy in CRC screening. The
statements were discussed and debated based on feedback from
the first vote. The second vote was held at the end of the talks,
using electronic keypads to ensure anonymity.
For statements on which consensus could not be reached,
further discussions were conducted. Statements were revised
accordingly. Then, the third and last vote was taken electro-
nically using the keypads. Each statement was graded to
indicate the level of evidence available and the strength of
recommendation by the whole group (table 1).
Funding sources
An unrestricted education grant was received from the Olympus
Medical Systems Corporation and Boston Scientific. A donation
was received from the Hong Kong Cancer Fund to support the
Consensus Conference. The meeting was supported in part by
the KC Wong Education Foundation and the Wei Lun
Foundation of the Chinese University of Hong Kong. To avoid
conflict of interest, industrial partners were not allowed to
participate in the discussion and iteration in the Consensus
Conference. None of the sponsors voted in the drawing up of
the consensus statement. Some ethnic groups (eg, Japanese,
Korean and Chinese) in Asia are more susceptible than others to
CRC.
RESULTS
A 2-day Consensus Conference was held on 15–16 September
2007 under the auspices of the Asia Pacific Society of Digestive
Endoscopy. Representatives from 14 Asian-Pacific countries/
regions participated in the meeting: these included Australia,
Brunei, China, Hong Kong, India, Indonesia, Japan, Malaysia,
Philippines, Singapore, South Korea, Taiwan, Thailand and
Vietnam. A total of 25 statements were presented for the first
vote. Fifty members participated in the voting.
EPIDEMIOLOGY OF COLORECTAL NEOPLASIA
Statement 1. Colorectal cancer is one of the most common
cancers in Asia in both males and females
Level of agreement: a, 90%; b, 10%; c, 0%; d, 0%; e, 0%
Quality of evidence: II-3
Classification of recommendation: A
Reports from the World Health Organization (WHO) data
set2 and individual countries or cities in Asia show that the
incidence of CRC is on a rapidly rising trend in regions within
countries such as China, Japan, Korea and Singapore.3–9 The
increase in number of new cases of CRC per year is witnessed in
both men and women. However, not all countries in Asia
witness the same degree of rise in incidence of CRC. For
example, in East Asian countries such as Indonesia, Thailand,
Vietnam and India, CRC is not the top cancer in either males or
females. The group also recognised that there is a lack of
adequate cancer registries in many Asian countries. Without
such reliable figures, some reservations remain in certain
countries in indicating an epidemic of CRC in the Asia Pacific
Region.
Statement 2. The incidence of CRC is similar to that of the West
Level of agreement: a, 37%; b, 47%; c, 14%; d, 2%; e, 0%
Quality of evidence: II-3
Classification of recommendation: B
The group considered that in high incidence countries such as
Japan, Korea, Singapore and Hong Kong, the incidence of CRC
is comparable with or approaching that of Western countries.10
Direct comparison figures are available from a study comparing
Japanese with the white population of the USA which showed
that the rates of CRC of these two populations were very
similar.11 However, such direct comparison studies are few. In
other countries such as India, Philippines and Vietnam, there is
still a gap in the incidence of CRC between these countries and
the West. There is a strong feeling that countries with an
obviously rising CRC incidence are more ‘‘Westernised’’ in
lifestyle, especially in dietary habit, with increased consumption
of high fat and protein but less fibre in the diet. The change is
more evident in urban cities than in rural areas of the same
country.7 Yet, the effects of lifestyle and dietary habit
modification on the changing epidemiology of CRC in Asia
need to be more adequately studied to confirm this impression.
Statement 3. The incidence of advanced neoplasm in
symptomatic and asymptomatic Asians is comparable with the
West
Level of agreement: a 37%; b, 43%; c, 16%; d, 4%; e, 0%
Quality of evidence: II-2
Classification of recommendation: B
Advanced neoplasia is defined as adenoma with a diameter of
>10 mm, a villous adenoma (ie, at least 25% villous), an
adenoma with high grade dysplasia or invasive cancer. There are
a few studies in Asian populations investigating the incidence of
advanced neoplasm in asymptomatic individuals in the Asia
Pacific region. A study in Hong Kong which recruited
asymptomatic subjects in a Chinese population showed that
4.4% had advanced neoplasia.12 Similar figures have been
reported in a screening colonoscopy study in asymptomatic
subjects among Koreans (4.1%)13 and Chinese (3.0%).14 Two
studies that involved multiple centres in Asia that studied
Guidelines
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symptomatic and asymptomatic populations have reported the
incidence of advanced neoplasm as 7.8%15 and 4.5%, respec-
tively.16 These figures are comparable with the larger Western
series using colonoscopy as a screening tool for colorectal
neoplasm.17–20 Depending on the method of recruitment, studies
enrolling asymptomatic individuals for screening may introduce
selection bias by recruiting more health-conscious subjects and
hence underestimate the true prevalence of the conditions. This
phenomenon may occur in studies from both the East and the
West.
Statement 4. While the death rate of CRC is declining in the
West, Asia continues to see rising mortality
Level of agreement: a, 78%; b, 20%; c, 0%; d, 2%; e, 0%
Quality of evidence: III
Classification of recommendation: C
Reports from the American Cancer Society in 2007 showed
that the number of Americans who died of cancer has dropped
for a second consecutive year21 and it was probably caused by ‘‘a
combination of factors including a decrease in cigarette smoking
among men, wider screening for colon cancer…’’22 ‘‘By far the
greatest decrease in mortality has been in colorectal cancer’’.23 A
similar decline in CRC mortality has been reported in Europe.24
On the contrary, according to the WHO mortality database,
CRC mortality has doubled in both men and women over the
last three decades in Taiwan.25 In Korea, the National Cancer
Center reported a decline in mortality from stomach and liver
cancer but an increase in CRC.26 In China, the National Census
Data also demonstrated a decline in mortality related to cancer
of the oesophagus, and gastric and liver cancer, but the age-
adjusted mortality from CRC has increased in both urban and
rural men.27
Statement 5. There are some ethnic groups (eg, Japanese,
Korean and Chinese) in Asia who are more susceptible to CRC
Level of agreement: a, 49%; b, 43%; c, 6%; d, 0%; e, 2%
Quality of evidence: II-c
Classification of recommendation: B
Existing evidence suggests that there are some ethnic
difference in susceptibility to CRC. In Singapore, the incidence
of CRC is significantly lower among Indians and Malays than
among Chinese.28 29 In Malaysia, the same phenomenon has
been reported in a population of mixed ethnic cultures.30 In the
multinational studies conducted by the Asia Pacific Working
Group on CRC, Japanese, Korean and Chinese were found to
have a higher risk of advanced neoplasia in the colon.15 16 If
advanced neoplasia is considered a premalignant condition,
these results will infer that the incidence of CRC is higher in
these ethnic groups than in the others (eg, Indians, Thais and
Filipinos). The higher incidence among Chinese and the lower
incidence among Indians living in the same country mirror the
incidence rates in their countries of origin even though both
racial groups migrated more than three generations ago. These
observations on racial differences suggest that genetic factors
have an important aetiological role in CRC development,
although differences in dietary habit and lifestyle might also
contribute. An interesting study from Israel showed that Arabs
born in Israel had a much lower CRC incidence than Israeli-born
Jews, and this trend persisted over time.31 This observation
again supports the notion of genetic influence on CRC
development. However, the fact that the incidence of CRC
among Jews rose concomitantly with Westernisation of their
lifestyle hints that environmental influences cannot be
neglected.
COLORECTAL POLYPS
Statement 6. Distribution of polyps between Asians and
Caucasians is similar
Level of agreement: a, 22%; b, 61%; c, 8%; d, 8%; e, 2%
Quality of evidence: II-2
Classification of recommendation: B
There are very few direct comparisons of the incidence of
CRC or polyps between Asian and Caucasian populations. A
study comparing Chinese in Taiwan versus Caucasians in
Seattle suggested that Asians are more likely to have distally
located colorectal neoplasia.32 However, the distribution of
advanced neoplasia (including advanced adenoma and invasive
cancer) is not significantly different between the two studied
populations. Comparing three studies from Caucasian popula-
tions17–19 with four studies from Asian populations12 14 16 33 and
one from Australia,34 there are more distally located polyps in
the Asia Pacific studies. In Asia, 30% of polyps are proximal,
57% are distal and 13% are synchronous. In the West, 49% of
polyps are proximal, 49% are distal and 2% are synchronous.
However, the distribution of advanced neoplasia is not
significantly different between the East12 13 16 34 and the
West.17 18 35 The proximal, distal and synchronous advanced
neoplasias are 29%, 52% and 19% in Asia, and 35%, 59% and 6%
in the USA (table 2). Studies from Asia showed that 53–68% of
proximal advanced neoplasias were found in patients without a
distal lesion. This figure is also comparable with that reported in
the West. The similar distribution of colorectal polyps implies
that arguments used to recommend full colonoscopy instead of
flexible sigmoidoscopy in CRC screening can be applied in Asia.
However, it is worth pointing out that there are some variations
in the definitions of distal colonic disease in the literature. Some
use findings in the last 40 cm from the anal verge on
Table 1 Quality of evidence, classification of recommendation and
voting on recommendation
Category and grade Description
Quality of evidence
I Evidence obtained from at least 1 RCT
II-1 Evidence obtained from well-designed control trials
without randomisation
II-2 Evidence obtained from well-designed cohort or case–
control study
II-3 Evidence obtained from comparison between time or
places with or without intervention
III Opinion of respected authorities, based on clinical
experience and expert committees
Classification of
recommendation
A There is good evidence to support the statement
B There is fair evidence to support the statement
C There is poor evidence to support the statement but
recommendation made on other grounds
D There is fair evidence to refute the statement
E There is good evidence to refute the statement
Voting on
recommendation*
a Accept completely
b Accept with some reservation
c Accept with major reservation
d Reject with reservation
e Reject completely
*Statements for which .80% of participants voted a, b or c were accepted.
RCT, randomised controlled trial.
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withdrawal of the colonoscope12 and others define distal lesions
as findings beyond the splenic flexure,17 or lesions in the
descending colon, sigmoid colon and rectum.14 These discrepant
definitions of distal colon limit the interpretation of adenoma
distributions reported in the literature.
Statement 7. There is a trend towards proximal migration of
polyps in the colon in Asian subjects
Level of agreement: a, 41%; b, 39%; c, 18%; d, 2%; e, 0%
Quality of evidence: III
Classification of recommendation: C
Data from the Japan Society for Cancer of the Colon and
Rectum from 1974 to 1994 reviewed a right shift of CRC within
a period of two decades.36 The increase in the percentage of
right-sided CRC was accompanied by a continuous decline in
the percentage of rectal cancer in both males and females in all
age groups. A single-centre retrospective cohort study in Hong
Kong showed that in the last 10 years there has been an age-
adjusted increasing trend of colorectal polyps in the right colon
and a decrease in incidence in the left colon.10 However, this
study was limited by its retrospective nature and by not
representing a predefined population. In Australia, a study
reviewed endoscopy reports on 2578 subjects and found that
51% of polyps are right-sided, 20% are left-sided and 29% are
synchronous.34 The incidence of right-sided adenoma increases
with age, and hence evaluation of the proximal bowel is
particularly important in older people. In Japan, a cohort study
enrolling 23 444 consecutive asymptomatic subjects suggested
that the right shift is a phenomenon resulting from ageing.37
The Japan Polyp Study also reported that more than half of the
advanced neoplasias are in the right colon.38 A contradictory
finding was reported from Singapore.39 This study showed that,
from 1968 to 1992, the age-standardised rate of cancer in the
distal colon was doubled in the right colon (2–3% annually) but
more than doubled in the distal colon (3–4% annually). The
incidence of rectal cancer was stable in Singapore. A similar
observation was reported in Malaysia.40 The wider accessibility
of screening colonoscopy in some Asian countries together with
the ageing population would at least partly account for the
apparent increase in proximal CRC. Further studies with a long
timeline will be needed to substantiate this change in
epidemiology.
Statement 8. Non-polypoid adenoma is not uncommon among
Asians
Level of agreement: a, 82%; b, 16%; c, 0%; d, 0%; e, 2%
Quality of evidence: II-2
Classification of recommendation: A
Flat and depressed lesions were first reported by Muto.41 In
Japan, it has been reported that the prevalence of flat depressed
and flat elevated lesions constituted around 3% and 18% of
neoplastic lesions found on colonoscopy.42 Submucosal invasion
was found much more commonly in flat depressed lesions
compared with elevated lesions. Kudo reported that around 1.8–
2.3% of colonic neoplasias are depressed lesions.43 In Japan, de
novo cancers—that is, cancers not arising from pre-existing
adenomas, are believed to develop from these non-polypoid
lesions. It has been estimated that 18.6% of CRC in men and
27.4% of CRC in women are so-called de novo cancers in
Japan.44 Over 80% of de novo cancers were invasive cancers.
With the increasing awareness of these lesions, the increasing
use of chromoendoscopy and new endoscopic imaging technol-
ogy, there are increasing reports of flat lesions. In Singapore, 91
flat lesions were found in a cohort of 491 236 patients without
using chromoendoscopy or magnifying colonoscopy.45 In Korea,
18 flat adenomas were identified using chromoendoscopy
(indigocarmine) which would have been missed by conventional
colonoscopy.46 In Malaysia, 29 adenomas were identified in 12
patients, of which 14 were flat.47 The flat adenomas found in
this study were ,5 mm in size. Despite the advancement in
endoscopy imaging technology, the detection of non-polyploid
adenoma and de novo cancer remains a challenge. However, the
necessity of discovering these small lesions is yet to be
determined. Small, polypoid adenomas without villous struc-
ture or high grade dysplasia are not associated with an increased
risk for CRC. Whether small flat adenomas are of greater
significance remains to be determined with certainty.
Statement 9. Certain types of hyperplastic polyps are associated
with an increased risk of cancer
Level of agreement: a, 80%; b, 20%; c, 0%; d, 0%; e, 0%
Quality of evidence: II-3
Classification of recommendation: A
It is well known that hyperplastic polyposis syndrome is
associated with an increased potential for developing into CRC
whereas a typical small and distal hyperplastic polyp (with no
dysplasia) has little malignant potential. However, subsets of
hyperplastic polyps are now being described and the terminol-
ogy is evolving. The ability to distinguish between hyperplastic
polyp, admixed hyperplastic polyp/adenoma and serrated
adenoma (a form of hyperplastic polyp with propensity for
progression but without distinctive cytological dysplasia) is
debated among pathologists. While the majority of CRCs
develop through the adenoma–carcinoma sequence with APC,
K-Ras, DCC and p53 mutations, it is now clear that an admixed
hyperplastic polyp or serrated adenoma may have an alterna-
tive pathway for CRC carcinogenesis. Hyperplastic polyps
Table 2 Distribution of advanced colorectal neoplasm (ACRN) reported in studies in Asian vs Caucasian populations
Male (%)
Mean age
(years)
ACRN
Total (%) Proximal (%) Distal (%) Both (%)
Byeon16 Multicentre 860 (54.8) 54.4 39 (4.5) 17 (43.6) 19 (48.7) 3 (7.7)
Chiu14 Taiwan, China 1708 (59.8) 52.5 51 (3.0) 10 (19.6) 32 (62.7) 9 (17.6)
Liu33 Taiwan, China 5973 (52.3) 56.6 199 (3.3) 56 (28.1) 95 (47.7) 48 (24.1)
Sung12 Hong Kong 505 (44.4) 56.5 63 (12.5) 18 (28.6) 37 (58.7) 8 (12.7)
Distribution in Asian studies 19.6–43.6 47.7–62.7 7.7–24.1
Imperiale18 USA 1994 (58.9) 59.8 – 50 (45.0) 61 (55.0) –
Lieberman17 USA 3121 (96.8) 62.9 329 (10.5%) 101 (30.7) 201 (61.1) 27 (8.2)
Imperiale35 USA 906 (61) 44.8 32 (3.5%) 14 (43.8) 17 (53.1) 1 (3.1)
Distribution of ACRN in Caucasian studies 23.7–45.0 53.1–64.1 3.1–12.2
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associated with CRC may be associated with MLH-1 protein,
MSI and MLH1 promoter methylation.48 BRAF mutation and
aberrant promoter methylation leading to microsatellite
instability and methylation instability are common in serrated
adenoma and admixed polyps.49 50 A large, right-sided, sessile
hyperplastic polyp with certain architectural features (eg,
branching of crypts, dilation of base of crypts, horizontal
extension of crypts, etc.) should be completely removed and
carefully monitored.
Statement 10. Polyps 5–9 mm in size should be removed
Level of agreement: a, 75%; b, 20%; c, 2%; d, 3%; e, 0%
Quality of evidence: III
Classification of recommendation: C
Reports from the early 1990s showed that screening
sigmoidoscopy and removal of the polyp reduced CRC
mortality.51 52 The National Polyp Study which included
patients from the USA and the UK,53 and the Italian
Multicenter Study54 provided the strongest evidence that
removal of polyps reduced the risk of subsequent CRC.
Recently, long-term follow-up figures from the National Polyp
Study showed a reduction in mortality after polyps were
removed during screening colonoscopy.55 The Japan Polyp Study
Group conducted a retrospective study of a cohort of 5309
subjects who underwent colonoscopy from 1990 to 1995 and
followed-up for .3 years. In this period, polyps larger than
6 mm were removed.56 The cumulative hazard of developing
malignant disease for those who had a polyp ,5 mm was
comparable with that for those who had no polyp found on
index colonoscopy. On the other hand, those with polyps
measuring 6–9 mm have a cumulative hazard of developing
invasive cancer comparable with those with intramucosal
cancer.38 These are important data from Asia which lend
support to the removal of polyps 5–9 mm in size. The Japan
Polyp Study Group is now conducting a study randomising
polypectomised patients to be followed either at 3 years, or at 1
year and then 3 years to study the outcome of such surveillance
intervals in the context of finding new colonic lesions.
SCREENING TESTS FOR COLORECTAL NEOPLASIA
Statement 11. Faecal occult blood test (FOBT; guaiac-based and
immunochemical tests), flexible sigmoidoscopy and colonoscopy
should be recommended for CRC screening
Level of agreement: a, 74%; b, 18%; c, 6%; d, 2%; e, 0%
Quality of evidence: I
Classification of recommendation: A
FOBT, flexible sigmoidoscopy and colonoscopy are recom-
mended options for CRC screening in national guidelines from
the USA, the UK and Canada.57–60 Annual or biennial screening
with FOBT using a guaiac-based test or an immunochemical
test has been shown to reduce both CRC and CRC-related
mortality compared with no screening.61 62 Although the
sensitivity of a single FOBT is low, in the range of 30–50%,
repeated annual testing can detect as many as 92% of CRCs. It
is perceived that FOBT is a ‘‘cancer test’’ instead of a test for
polyps or adenoma. The advantage is that FOBT can be done at
home and is non-invasive, but the test needs to be repeated
every 1–2 years. Rehydration of the stool sample is not
recommended. Although rehydration of the guaiac-based test
increases sensitivity, the false-positive rate is also raised, leading
to unnecessary anxiety and unnecessary performance of
invasive tests. An immunochemical test may obviate the need
for dietary restriction.63 64 Recently, faecal immunochemical
tests for haemoglobin have been shown to be more sensitive
than the guaiac test for cancer and adenomas especially in Asian
subjects, probably due to lack of dietary interference.65 66
Flexible sigmoidoscopy performed every 5 years has been
shown in case-controlled studies to reduce mortality from
CRC.51 52 The preliminary findings of a randomised controlled
trial of screening flexible sigmoidoscopy have been reported, but
the result in terms of effectiveness on an intention-to-screen
basis at the population level is not yet available.67 The
recommendation of a 5 year interval was based on a cohort
study which showed that 5 years after a negative colonoscopy,
new advanced neoplasias are rare.68 The sensitivity of flexible
sigmoidoscopy in detecting advanced neoplasia is reported to be
35–70% and reduced the cancer risk in the rectum and sigmoid
by 50–60%.17–19 69 The recommended interval of screening is
shorter than for colonoscopy because flexible sigmoidoscopy is
less sensitive than colonoscopy even in the distal colon. This is
because of the quality of bowel preparation, the varied
experience of the examiners and the discomfort, which leads
to colonic spasm which may affect the depth of sigmoidoscope
insertion and hence the adequacy of the examination. Since up
to two-thirds of proximal advanced lesions in Asians are found
in the absence of distal lesions, the disadvantage of creating a
false sense of security using flexible sigmoidoscopy for screening
is noted.
The use of colonoscopy for screening is not supported by a
randomised controlled study but by indirect evidence. The
National Polyp Study has demonstrated a reduced incidence of
CRC53 and recently a reduced mortality from CRC among those
who underwent colonoscopy.55 Colonoscopy is the only
modality that allows removal of the adenoma and prevents
CRC. A similar study in Europe has confirmed the benefit of the
screening procedure.54 The effectiveness of colonoscopy is
dependent on the quality of the examination (see below).
Statement 12. Double-contrast barium enema (DCBE) is not a
preferred CRC screening test
Level of recommendation: a, 78%; b, 20%; c, 0%; d, 2%; e, 0%
Quality of evidence: III
Classification of recommendation: C
DCBE every 5 years is listed as one of the options in CRC
screening in national guidelines in North America. Like
colonoscopy, there is no randomised trial evaluating whether
screening DCBE reduces the incidence or mortality of CRC in
the average-risk population, and there has been no actual report
using barium enema in a true screening environment. The
sensitivity of DCBE is lower than that of colonoscopy and it
does not permit removal of polyps or biopsy of cancers. In a
study comparing DCBE and colonoscopy, the sensitivity of
DCBE for lesions .10 mm was 48% and for lesions of 6–9 mm
it was 35%.70 In the National Polyp Study, DCBE detected only
53% of adenomatous polyps 6–10 mm in size and 48% of those
.10 mm in size compared with colonoscopy.71 Because of its
lower sensitivity, even for large polyps, the Consensus Group
does not recommend DCBE as a first-line option for CRC
screening.
Statement 13. CT colonography is not currently a preferred CRC
screening test
Level of recommendation: a, 90%; b, 8%; c, 0%; d, 2%; e, 0%
Quality of evidence: III
Classification of recommendation: C
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Unlike DCBE, there is increasing evidence to suggest that CT
colonography is an accurate screening method for the detection
of colorectal neoplasia in asymptomatic average-risk adults.72 73
The sensitivity and specificity of the findings are also dependent
on the size of the polyps. Meta-analysis showed that sensitivity
is around 85% for polyps .9 mm, 70% for polyps 6–9 mm, and
50% for polyps ,6 mm.74 75 Studies have also shown that large
size (>10 mm in size) is the best prediction of advanced
neoplasia.76 According to this study, high grade dysplasia and
invasive cancer is very uncommon in medium sized (6–9 mm)
lesions, which justifies the use of size alone as a surrogate
measure for predicting advanced histological features. Since it is
not clear whether small polyps should be removed by
polypectomy, some radiologists recommended that polyps
,5 mm in size should not be reported. Patients with polyps
of 6–9 mm should have repeat CT at 1–2 yearly intervals.77
Patients with polyps that are 6–9 mm can have a repeat CT
colonography in 3 years, and polyps ,6 mm need not be
reported. In the literature, however, there is a discrepancy in the
results of CT colonography as a result of a difference in CT
collimation width, type of scanner and mode of imaging. The
use of a multidetector scanner equipped with 3-D flythrough
views that simulate colonoscopy may increase the sensitivity of
CT colonography. While in the expert centre, a randomised trial
of CT colonography compares favourably with conventional
colonoscopy,71 the results in non-expert centres are less
promising.78 Furthermore, acceptability in a true screening
population has not been fully explored. High cost, risk
associated with radiation and requirement for bowel prepara-
tion are the other factors hindering the use of CT colonography
as a primary screening method at this stage. In view of the
inaccessibility of cutting-edge imaging technology in some
Asian countries, the Consensus Group does not recommend
CT colonography as a CRC screening tool at this stage.
However, the group believes that with increased accessibility,
CT colonography may become a recommended tool for CRC
screening in the future.
Statement 14. In resource-limited countries, FOBT is the first
choice for CRC screening
Level of recommendation: a, 72%; b, 18%; c, 6%; d , 4%; e, 0%
Quality of evidence: I
Classification of recommendation: C
FOBTs are used in screening to refine the likelihood of cancer
being present and so direct scarce colonoscopy resources to
those more likely to have neoplasia.79 A large-scale case–control
study in Japan using immunochemical FOBT has shown a
decrease in CRC mortality by 70%.80 This benefit was witnessed
in both men and women in the cohort. Although the overall
rate of incidence of CRC has not been significantly reduced, a
reduction in advanced CRC was reported. A study from
Australia showed that CRC screening by FOBT is cost-effective
and comparable with other cancer screening programmes.81
More cost-effectiveness studies need to be done in Asia.
Despite the fact that FOBTs (guaiac or immunochemical
tests) are not diagnostically precise, many Western countries
consider that they are the best approach to population screening
because of their simplicity and high acceptance by asympto-
matic subjects even in countries with a well-developed
healthcare system. Clearly, in resource-limited countries in
Asia, in order to have a population impact, FOBT is the most
affordable test.
Statement 15. Following a negative colonoscopy, a repeat
examination should be performed in 10 years
Level of recommendation: a, 27%; b, 53%; c, 8%; d, 12%; e, 0%
Quality of evidence: II-3
Classification of recommendation: C
The choice of a 10-year interval between screening examina-
tions for average-risk subjects after a negative colonoscopy is
based on estimates of the sensitivity of colonoscopy and the rate
at which advanced neoplasia develops.53 82 Colonoscopy is not
perfect and it can still miss colorectal adenoma or even cancer.
The rate of new or missed CRC within 3 years after
colonoscopy has been reported as around 5% in the proximal
colon and around 2% in the distal colon.83 The chance of missing
a diagnosis is higher in older subjects, those with diverticular
disease, right-sided or transverse lesions, suboptimal bowel
preparation and when colonoscopy is performed by internists or
family doctors in their office. A large series of colonoscopy
screening showed that 0.3–0.9% of CRC can be missed.84–86
These so-called interval cancers after colonoscopy could be due
to genuinely new and fast growing lesions,87 incomplete
removal of polyps85 or missed lesions. Withdrawal time during
colonoscopy is found to correlate with adenoma detection
during screening colonoscopy.88 89 In essence, the impact and
success of colonoscopy screening depend on the quality of the
procedure. The potential benefit and risk of screening change in
elderly patients of different life expectancies and the age for
stopping screening should be considered.90 Even though the
prevalence of neoplasia increases with age, screening in elderly
persons .80 years of age results in only a modest gain in life
expectancy and thus may not be desirable.91
RISK STRATIFICATION IN CRC SCREENING
Statement 16. The age-adjusted incidence of CRC is higher in
men than in women
Level of agreement: a, 82%; b, 16%; c, 0%; d, 0%; e, 2%
Quality of evidence: II-2
Classification of recommendation: A
In many Asian countries, the age-adjusted incidence of CRC
is found to be higher in men than in women.3–10 While the exact
mechanism of the hormonal effect on colorectal neoplasia is still
unclear, in a prospective Japanese study pregnancy was found to
be associated with reduced risk of CRC in women.92 It is
postulated that female sex hormones reduce the risk of CRC.
Indeed, this observation was also reported in the VA
Cooperative Study 380 and suggested that women may start
screening at a later age because of their relatively low incidence
of colorectal neoplasia at the age of 50–55 years.19 The fact that
the age-adjusted incidence in CRC is lower in women, however,
does not imply that screening is less effective in women. In a
large population-based Japanese cohort study using FOBT-
selected cases for colonoscopy screening, mortality reduction
was achieved in both men and women.80
Statement 17. CRC screening should begin at the age of 50
Level of agreement: a, 35%; b, 57%; c, 6%; d, 2%; e, 0%
Quality of evidence: II-2
Classification of recommendation: B
The prevalence of colorectal neoplasia increases with age. As
the risk of CRC starts to escalate at the age of 50 years, most
national guidelines recommend that screening programmes
should begin by this age.57–60 Screening colonoscopy studies in
Asia also confirm that at the age of 50 the risk of finding
advanced neoplasia is significantly increased from around 1% to
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.3%.12–15 Therefore, the Consensus Group showed strong
support for starting CRC screening at the age of 50 years.
From the large population-based cohort study in Japan using
FOBT for CRC screening, the best age to start screening was
50–59 years.78 The group also noted that in each age group,
however, other factors such as gender, family history and race
may affect the outcome of CRC screening. Since Asia represents
a very heterogeneous population, it is desirable to have a
formula stratifying the risk according to age, gender, race and
family history to select those who have the highest CRC risk for
priority in a screening programme. A risk stratification strategy
using colonoscopy and CT colonography has been described in
the West.93 94 This would be a very useful way of making the
best use of limited resources in many Asian countries. A two-
tier approach has been proposed in Taiwan, which may reduce
the workload on colonoscopy without jeopardising the efficacy
of screening.95 This kind of study would need further validation.
Statement 18. First-degree relatives of patients with CRC are at
an increased risk and thus should receive screening earlier
Level of agreement: a, 78%; b, 20%; c, 0%; d, 2%; e, 0%
Quality of evidence: III
Classification of recommendation: C
A prospective study showed that among first-degree relatives
of CRC patients, the age-adjusted risk of CRC was 1.72.96 With
two or more first-degree relatives, the risk is further escalated.
For those under the age of 45 who had one or more affected
first-degree relatives, the relative risk was increased by more
than fivefold. Colonoscopy screening in first-degree relatives of
patients with sporadic CRC has been demonstrated to yield a
higher rate of finding colorectal neoplasia.97 The odds ratios
(ORs) reported were 1.5 for adenoma, 2.5 for large adenoma and
2.6 for high risk adenoma. A study from Italy also showed that
compared with subjects with no family history, asymptomatic
patients with one first-degree relative with CRC had nearly
double the risk of developing adenomatous polyps.98 A meta-
analysis of pooled data from 27 case–control studies indicates
that the first-degree relatives of a patient with CRC have an
increased risk of colon cancer of 2.42 and of rectal cancer of
1.89.99 This applies to both parents and siblings suffering from
the disease. This phenomenon is also observed in a study from
Taiwan in which 234 immediate family members of 186 CRC
patients were screened.100 The immediate family members were
at increased risk for advanced neoplasia, with an OR of 4.5.
Individuals with index cancer relatives diagnosed at ,50 years
or male relatives were found to have an even higher risk of
advanced neoplasia.
Statement 19. Smoking increases the risk of CRC
Level of agreement: a, 51%; b, 31%; c, 12%; d, 4%; e, 2%
Quality of evidence: II-2
Classification of recommendation: B
There are studies in Asia, especially in Japan, China and
Singapore, investigating the effects of cigarette smoking and the
risk of CRC. A case–control study in Japan showed smoking in
the past 10 years is significantly associated with risk of sigmoid
and rectal adenoma.101 A larger and more recent study from
Japan confirms the association of smoking and CRC.102 The
effect of smoking has been observed to be related to the number
of cigarettes consumed and the age of starting smoking.103
Current smokers have a higher risk than ex-smokers, and men
and women were equally affected. It has been estimated that
approximately half of the CRC cases in Japan can be prevented
by tobacco and alcohol control in middle-aged and elderly
Japanese men. The relationship of smoking and alcohol
consumption to CRC was studied in Chinese living in
Singapore.104 In this population-based study, cigarette smoking
was associated with an increased risk of rectal but not colonic
cancer. Compared with non-smokers, light smokers have an
increased risk of 1.43 and heavy smokers of 2.64 of developing
rectal cancers. Smoking appears to interact with alcohol
consumption in an additive manner in affecting the risk of
rectal cancer.
Statement 20. Obesity increases the risk of CRC
Level of agreement: a, 47%
Quality of evidence: II-2
Classification of recommendation: A
Obesity has been found to increase the risk of CRC. A meta-
analysis reported a relative risk of CRC of 1.37 for overweight
and obese men, and the associated risk appears to be higher for
men than for women.105 Epidemiological studies have also
shown in a Korean population that patients with metabolic
syndrome had an increased risk of colorectal adenoma (OR
1.51).106 The association with metabolic syndrome was more
evident for proximal, multiple (.3) and advanced adenoma. In
Japan, a nationwide prospective study which included .43 000
women and 58 000 women aged 40–70 showed, after adjust-
ment for the lifestyle factors, a significant positive correlation of
CRC with baseline body weight.107 Women with baseline bdoy
mass index (BMI) .28 kg/m2 had a relative risk of 2.4 for CRC
compared with those with a BMI of 20–22 kg/m2. BMI was also
found to have a positive correlation with adenoma of the colon
in Japan and Korea.108 109 This trend has not been demonstrated
in man. Hyperinsulinaemia may be an important factor, but the
role of oxidative stress initiated by hyperglycaemia is another
possible mechanism. The lack of physical activity leading to
overweight has been identified as a risk factor for CRC in a
study from Shanghai.110 A recent study from Hong Kong also
showed that those who underwent investigations for coronary
heart disease are more likely to have CRC.111 Metabolic
syndrome among this group of patients is an independent risk
factor for the condition.
Statement 21. Screening for CRC should be a national health
priority in most Asian countries
Level of agreement: a, 57%; b, 33%; c, 8%; d, 2%; e, 0%
Quality of evidence: III
Classification of recommendation: C
In North America and Europe, as well as Australia and New
Zealand, there is a widespread scientific agreement on the value
of CRC screening. CRC screening is endorsed by the American
Cancer Society, the US Preventive Services Task Force, the
Multi-Society Taskforce on Colorectal Cancer, the American
College of Gastroenterology, the American Gastroenterological
Association, the American Society of Gastrointestinal
Endoscopy, the American College of Physicians, the British
Society of Gastroenterology, the Canadian Task Force on
Preventive Health Care and the Royal Colleges of Physicians
in the UK, to name just a few.57–60 Screening is available in
different settings, but the vast majority of screening activities
are still opportunistic and uncoordinated. In certain localities,
large healthcare systems (e.g. Kaiser Permanente of North
California and the Veteran’s Administration) have developed
organised screening for their populations. Local programmes are
also found in other regions (eg, the State of Maryland and New
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York City). In the USA, Medicare added coverage for CRC
screening in 2000. Laws have been enacted in nearly half of the
states in the USA requiring private insurers to pay for CRC
screening tests. Legislation was introduced in the US Congress
in 2007 to create a CRC screening, diagnostic and treatment
programme for poor and/or uninsured citizens. In Europe, a
public health programme has developed a comprehensive set of
recommendations for cancer screening, and CRC screening was
added in 2003. In a recent survey conducted by the
International Digestive Cancer Alliance (ICDC) across Europe,
21 out of 39 nations have reported national screening guidelines
promoted by medical and professional organisations.112 Fifteen
countries are currently performing some form of population
screening programmes and seven others have feasibility studies
underway. Respondents from 20 countries where screening is
not taking place indicated a lack of official recognition of the
importance and value of CRC screening. Lack of financial
support is identified as the primary barrier to screening.
Germany is the European country with the largest screening
programme using guaiac-based FOBT. Since 2002, .2.1 million
screening colonoscopies have been performed, detecting ade-
noma in about 20% of subjects and CRC in 0.6–0.8% of
subjects.
In Asia, a national guideline is available only in Australia,
Japan, Korea, Taiwan and Singapore.113–117 Despite these guide-
lines, the uptake of CRC screening is relatively low. In Korea,
the government covers 50% of the cost of CRC screening and
100% for low-income individuals. Taiwan is the only country
with free mass screening for CRC under the national health
insurance scheme. CRC screening is endorsed but not funded in
most Asian countries. In countries such as Brunei, China, India,
Indonesia, Malaysia, Philippines, Thailand and Vietnam, a
national guideline is not available. Government support for
CRC screening is very limited. The Consensus Group urges
strong support from Asian health authorities to promote CRC
screening in the Asia Pacific region.
Statement 22. Research on barriers to CRC screening should be
conducted in various Asian countries
Level of agreement: a, 86%, b; 14%; c, 0%; d, 0%; e, 0%
Quality of evidence: II-3
Classification of recommendation: B
Adherence to guidelines on screening is low even in Western
countries. In Japan, around 17% of the eligible population
participates in the immunochemical FOBT.118 In Canada, 23.5%
of eligible respondents received screening.119 In the USA, the
compliance rate was low and has only risen to 40–60% in recent
years.120 Only a limited number of studies have investigated the
factors that play a major role in compliance/non-compliance
with colon screen advice, and they have yielded somewhat
inconsistent findings. A recent study from Hong Kong
employed the Health Belief Model to study the knowledge,
behavioural and psychological obstacles to CRC screening
tests.121 Knowledge of CRC symptoms and risk factors,
recommendation by a doctor and the availability of health
insurance are positively associated with uptake of screening
tests. On the other hand, health, psychological and access
barriers, and perceived negative personal and family conse-
quences of CRC are negatively associated with uptake of the
screening test. The Asia Pacific Working Group on CRC is
undertaking a similar study to compare the health-seeking
behaviour and obstacles to screening tests in different cultures.
This kind of study will provide important information for the
successful implementation of CRC screening in the region.
Statement 23. Education of the public is essential in promoting
CRC screening
Level of agreement: a, 96%; b, 4%; c, 0%; d, 0%; e, 0%
Quality of evidence: I
Classification of recommendation: A
In most Asian societies, public knowledge of CRC is poor and
uptake of screening tests is expected to be low. Fewer than 10%
of the Hong Kong Chinese are aware that CRC is the second
most common cancer in their locality.122 Most Chinese believe
that ‘‘screening’’ is needed only when they develop symptoms
of cancer. Only one-third of the Singaporean Chinese know that
they should go for screening even if asymptomatic.123 Over 70%
of individuals cannot name a single screening method for CRC.
In both of these studies, there was little recommendation
offered to intervene in existing low awareness and willingness
to participate in CRC screening. A population survey suggested
that male subjects above 50 years of age were significantly
deficient in knowledge of CRC symptoms and the perceived
benefits of screening.121 Educating this group would be
important as they are the ones who may benefit from CRC
screening.
Statement 24. Family doctors should be engaged in promoting
CRC screening
Level of agreement: a, 82%; b, 18%; c, 0%; d, 0%; e, 0%
Quality of evidence: I
Classification of recommendation: A
Family doctors play a pivotal role in recommending asympto-
matic individuals for CRC screening. A study in Iowa in the
USA shows that the strongest predictors of patient’s compli-
ance with CRC screening, other than symptoms, were patient
recollection of a doctor’s recommendation and documentation
by the doctor of advice to their patients.124 In two population
surveys in Hong Kong, a recommendation from the family
doctor was found to have the highest impact on the patients’
compliance with CRC screening.121 122 Recommendation by a
doctor increases the likelihood of having a CRC screening test
by 21 times.121 Why are some family doctors not interested in
recommending CRC screening? Previous studies have shown
that lack of knowledge and training, lack of time and
opportunity, lack of financial support for the patients in
participating in screening and inconsistency in recommenda-
tions are the most important reasons for their reluctance to
advise their patients.125 Education and training for family
doctors should be an effective strategy to promote CRC
screening.
Statement 25. Nurses in Asia should be trained to perform
flexible sigmoidoscopy for CRC screening
Level of agreement: a, 6%; b, 4%; c, 30%; d, 30%; e, 30%
No consensus reached
The Consensus Group noted that in the UK, the USA and
Canada, there are nurse-run flexible sigmoidoscopy pro-
grammes.126–128 There is at least one nurse practitioner-directed
colonoscopy programme in the USA (Alaska). The advantages
of recruiting nurses to perform endoscopy are to speed up the
process of CRC screening and to relieve the endoscopy work-
load. The enhanced contributions of nurses will also strengthen
the nursing profession to become more competent and
independent. A stringent training programme and other
academic qualifications may ensure the competence of nurse
endoscopists. In order to implement nurse-led CRC screening by
flexible sigmoidoscopy or colonoscopy, due recognition by the
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nursing council and proper licensing criteria will be required.
Among the members of the Consensus Group, there was a very
divergent view. Issues of liability, third-party reimbursement,
lack of medical support, lack of policies and guidelines on this
have been discussed. The majority of members have reservations
on this issue and a consensus view could not be reached in the
meeting. However, despite the hurdles, the Consensus Group
believes that other than endoscopy, nurses can play a very
important role in patient education, coordination of service and
tracking individuals tested positive by FOBT.
CONCLUSION
These are the first Asia Pacific Consensus statements formu-
lated based on evidence in the literature, national registries and
local data, input from international experts and thorough
discussion among members of the Asia Pacific Working Group
for Colorectal Cancer. It provides a basis for further elaboration
and modification to suit the needs of each individual Asia Pacific
country/region. There are areas which cannot be covered in the
present statements. These include the recommendations for
hereditary CRC and genetic counselling policy, lifestyle risk
factors and intervention, cultural differences in health-seeking
behaviour, among others. Future studies in the Asia Pacific
region should aim at investigating the effects of culture on
compliance with CRC screening, the effects of genetic and
environmental factors on CRC development and the practical
use of guaiac-based and immunochemical FOBTs in different
Asian populations.
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ANSWER
From the question on page 1101
During endoscopy, it was found that a wooden toothpick
was embedded in the posterior wall of the distal antrum
surrounded by a subtle, rounded bulge seen actively to exude
a small amount of pus from its centre (fig 1 of the
Question). An overtube was placed and a 33 mm long
toothpick was recovered. Figure 1 shows the lesion after
removal of the stick. In retrospect, the patient had no
recollection of having swallowed a toothpick. There was
marked diminution of the patient’s pain postprocedure. A
follow-up abdominal x ray and CT scan to rule out
perforation and abscess were unremarkable. The patient
was admitted to hospital for 1 day, and subsequently
discharged in a stable condition.
Clinicians should include inadvertent foreign body inges-
tion in the differential diagnosis for abdominal pain and
gastrointestinal bleed. Patients should be warned of the
potential hazards of toothpicks and cocktails sticks, frag-
ments of which may be left in club sandwiches which have
been cut in half.
Patient consent: Patient consent has been received for publication of the case
details and the figures in this paper.
Gut 2008;57:1176. doi:10.1136/gut.2007.129981a
Figure 1 A subtle bulge with pus seen after the removed of the tooth
pick from the distal antrum of the stomach.
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